[关键词]
[摘要]
阿柏西普是一种人重组融合蛋白，作为一种可溶性血管内皮生长因子(VEGF)家族诱饵受体，包括VEGF-A、VEGF-B和胎盘生长因子(PLGF)，从而抑制这些受体介导的下游信号。与雷珠单抗和贝伐单抗相比，阿柏西普与VEGF-A的所有亚型均具有更高的亲和力。阿柏西普已被批准用于治疗新生血管性年龄相关性黄斑变性(nARMD)，国外大量临床研究显示其能很好地改善患者最佳矫正视力，减轻黄斑水肿和降低并发症，成为治疗nARMD患者的另一个选择，然而国内大样本应用时间尚短，国内相关研究较少，本文对阿柏西普治疗nARMD的临床应用进行综述。
[Key word]
[Abstract]
Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor(VEGF)family members. VEGF-A, VEGF-B and placental growth factor(PLGF)were included in VEGF family that could inhibit downstream signalling mediated by these ligands. Aflibercept binds to all isoforms of VEGF-A with high affinity, and presented a markedly higher affinity compared with ranibizumab or bevacizumab. Intravitreal injection aflibercept has been approved for the treatment of patients with age-related macular degeneration(ARMD). Numerous studies showed it could improve best corrected visual acuity(BCVA), reduce macular edema and with fewer complications that has been another choice for ARMD patients. However, studies of participation time with large sample are lacking, and relevant studies are limited in China. Contribution in clinical efficacy, advancement in selection and use of medicines, safety and limitations with aflibercept will be here summarized.
[中图分类号]
[基金项目]
海南省卫生计生行业科研项目(No.18A200168)
